Cardiomyopathy, familial dilated

被引:0
|
作者
Matthew RG Taylor
Elisa Carniel
Luisa Mestroni
机构
[1] University of Colorado Health Sciences Center,University of Colorado Cardiovascular Institute and Adult Medical Genetics Program, Department of Internal Medicine
来源
Orphanet Journal of Rare Diseases | / 1卷
关键词
Genetic Counseling; Cardiac Resynchronization Therapy; Carvedilol; Angiotensin Converting Enzyme Inhibitor; Left Ventricular Assist Device;
D O I
暂无
中图分类号
学科分类号
摘要
Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by ventricular dilatation and impaired systolic function. Patients with DCM suffer from heart failure, arrhythmia, and are at risk of premature death. DCM has a prevalence of one case out of 2500 individuals with an incidence of 7/100,000/year (but may be under diagnosed). In many cases the disease is inherited and is termed familial DCM (FDC). FDC may account for 20–48% of DCM. FDC is principally caused by genetic mutations in FDC genes that encode for cytoskeletal and sarcomeric proteins in the cardiac myocyte. Family history analysis is an important tool for identifying families affected by FDC. Standard criteria for evaluating FDC families have been published and the use of such criteria is increasing. Clinical genetic testing has been developed for some FDC genes and will be increasingly utilized for evaluating FDC families. Through the use of family screening by pedigree analysis and/or genetic testing, it is possible to identify patients at earlier, or even presymptomatic stages of their disease. This presents an opportunity to invoke lifestyle changes and to provide pharmacological therapy earlier in the course of disease. Genetic counseling is used to identify additional asymptomatic family members who are at risk of developing symptoms, allowing for regular screening of these individuals. The management of FDC focuses on limiting the progression of heart failure and controlling arrhythmia, and is based on currently accepted treatment guidelines for DCM. It includes general measures (salt and fluid restriction, treatment of hypertension, limitation of alcohol intake, control of body weight, moderate exercise) and pharmacotherapy. Cardiac resynchronization, implantable cardioverter defibrillators and left ventricular assist devices have progressively expanding usage. Patients with severe heart failure, severe reduction of the functional capacity and depressed left ventricular ejection fraction have a low survival rate and may require heart transplant.
引用
收藏
相关论文
共 50 条
  • [41] Communal Coping as a Strategy to Enhance Family Engagement in Dilated Cardiomyopathy
    Burke, Wylie
    Hovick, Shelly R.
    Jordan, Elizabeth
    Ni, Hanyu
    Kinnamon, Daniel D.
    Hershberger, Ray E.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2022, 15 (03): : E003541
  • [42] Therapeutic left ventricular assist device and apheresis on dilated cardiomyopathy
    Matoba, Y
    Okubo, H
    Nosé, Y
    ARTIFICIAL ORGANS, 2004, 28 (02) : 171 - 181
  • [43] Targeted Mono-Therapy for Newly Diagnosed Dilated Cardiomyopathy
    Rajapreyar, Indranee
    Samson, Rohan
    Ennezat, Pierre Vladimir
    Le Jemtel, Thierry H.
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : 686 - 689
  • [44] Tafazzin gene mutations are uncommon causes of dilated cardiomyopathy in adults
    Taylor, Matthew
    Slavov, Dobromir
    Salcedo, Ernesto
    Zhu, Xiao
    Ferguson, Deborah
    Jirikowic, Jean
    Di Lenarda, Andrea
    Sinagra, Gianfranco
    Mestroni, Luisa
    CARDIOGENETICS, 2011, 1 (01) : 9 - 12
  • [45] Dilated cardiomyopathy in children: moving beyond traditional pharmacologic therapy
    Cohen, Jordan A.
    Almodovar, Melvin C.
    CURRENT OPINION IN CARDIOLOGY, 2020, 35 (01) : 52 - 57
  • [46] Effect of benazepril on heart rate turbulence in patients with dilated cardiomyopathy
    Zhong, Jiang-Hua
    Chen, Xiao-Pan
    Zeng, Chun-Fang
    Yun, Mei-Ling
    Yang, Xin-Wei
    Chen, Yan-Fang
    Yao, Zhen
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2007, 34 (07) : 612 - 616
  • [47] Nonspecific intraventricular conduction delay predicts the prognosis of dilated cardiomyopathy
    Yuan, Yong
    Yang, Kai
    Liu, Qianjun
    Song, Weixiang
    Jin, Dongsheng
    Zhao, Shihua
    BMC CARDIOVASCULAR DISORDERS, 2023, 23 (01)
  • [48] Advances in heart failure therapy in pediatric patients with dilated cardiomyopathy
    Rupp, Stefan
    Jux, Christian
    HEART FAILURE REVIEWS, 2018, 23 (04) : 555 - 562
  • [49] Pacing treatment for dilated cardiomyopathy: optimization of resynchronization pacing in pediatrics
    Greene, E. Anne
    Berul, Charles I.
    CURRENT OPINION IN CARDIOLOGY, 2010, 25 (02) : 95 - 101
  • [50] Outcomes of Dilated Cardiomyopathy in Japanese Children A Retrospective Cohort Study
    Mori, Hiroki
    Yoshikawa, Tadahiro
    Kimura, Hitomi
    Ono, Hiroshi
    Kato, Hitoshi
    Ono, Yasuo
    Nii, Masaki
    Shindo, Takahiro
    Inuzuka, Ryo
    Horigome, Hitoshi
    Miura, Masaru
    Ogawa, Shunichi
    Shiono, Junko
    Furutani, Yoshiyuki
    Ishido, Mikiko
    Nakanishi, Toshio
    CIRCULATION JOURNAL, 2022, 86 (01) : 109 - 115